Feedback / Questions
SM2275 - StarMab Biomed
https://fox40.com/business/press-releases/ein-presswire/800645408/starmab-biomeds-first-in-class-dual-target-anti-tumor-drug-sm2275-for-novel-immunotherapy-receives-fda-ind-approval/
Apr 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next